TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

被引：92

作者：

Dreger, Peter ^{[1
]}

Schnaiter, Andrea ^{[2
]}

Zenz, Thorsten ^{[1
,2
,3
,4
]}

Boettcher, Sebastian ^{[5
]}

Rossi, Marianna ^{[6
]}

Paschka, Peter ^{[2
]}

Buehler, Andreas ^{[2
]}

Dietrich, Sascha ^{[1
]}

Busch, Raymonde ^{[7
]}

Ritgen, Matthias ^{[5
]}

Bunjes, Donald ^{[2
]}

Zeis, Matthias ^{[8
]}

Stadler, Michael ^{[9
]}

Uharek, Lutz ^{[10
]}

Scheid, Christof ^{[11
]}

Hegenbart, Ute ^{[1
]}

Hallek, Michael ^{[11
]}

Kneba, Michael ^{[5
]}

Schmitz, Norbert ^{[8
]}

Doehner, Hartmut ^{[2
]}

Stilgenbauer, Stephan ^{[2
]}

机构：

[1] Heidelberg Univ, Dept Med 5, D-69120 Heidelberg, Germany

[2] Univ Ulm, Dept Med 3, D-89069 Ulm, Germany

[3] Natl Ctr Tumor Dis, Dept Translat Oncol, Heidelberg, Germany

[4] German Canc Res Ctr, Heidelberg, Germany

[5] Univ Hosp Schleswig Holstein, Dept Med 2, Kiel, Germany

[6] Univ Pavia, Div Hematol, I-27100 Pavia, Italy

[7] Tech Univ Munich, Inst Med Stat & Epidemiol, D-80290 Munich, Germany

[8] Asklepios Klin St Georg, Dept Hematol & Stem Cell Transplantat, Hamburg, Germany

[9] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany

[10] Univ Med Berlin, Charite Campus Virchow Klinikum, Dept Med Hematol Oncol & Tumor Immunol, Berlin, Germany

[11] Univ Cologne, Dept Med 1, Ctr Integrated Oncol Cologne Bonn, D-50931 Cologne, Germany

来源：

BLOOD | 2013年 / 121卷 / 16期

关键词：

STEM-CELL TRANSPLANTATION; INTENSITY ALLOGENEIC TRANSPLANTATION; MINIMAL RESIDUAL DISEASE; MARROW-TRANSPLANTATION; SURVIVAL; FLUDARABINE; THERAPY; ERADICATION; TRISOMY-12; PREDICTOR;

D O I：

10.1182/blood-2012-11-469627

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

The purpose of this analysis was to provide 6-year follow-up of the CLL3X trial, which studied reduced-intensity allogeneic hematopoietic stem cell transplantation (HSCT) in patients with poor-risk chronic lymphocytic leukemia (CLL), and to investigate the effect of TP53, SF3B1, and NOTCH1 mutations on HSCT outcome. For 90 allografted patients, 6-year overall survival (OS) was 58% and 6-year event-free survival (EFS) was 38%. TP53, SF3B1, and NOTCH1 mutations were found in 30%, 26%, and 14% of the trial population, respectively. By univariate and multivariate analyses, the mutational status of the TP53, SF3B1, and NOTCH1 genes had no significant effect on OS and EFS. Studies of minimal residual disease confirmed durability of CLL eradication in mutated patients. We conclude that HSCT can provide long-term disease control in patients with poor-risk CLL independent of the presence of TP53, SF3B1, and NOTCH1 mutations. The trial has been registered at the US National Cancer Institute as #EU-20554, NCT00281983.

引用

页码：3284 / 3288

页数：5

共 22 条

[1]

NOTCH1 mutations in CLL associated with trisomy 12 [J].

Balatti, Veronica ;

Bottoni, Arianna ;

Palamarchuk, Alexey ;

Alder, Hansjuerg ;

Rassenti, Laura Z. ;

Kipps, Thomas J. ;

Pekarsky, Yuri ;

Croce, Carlo M. .

BLOOD, 2012, 119 (02) :329-331

[2]

Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis [J].

Boettcher, S. ;

Stilgenbauer, S. ;

Busch, R. ;

Brueggemann, M. ;

Raff, T. ;

Pott, C. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Doehner, H. ;

Hallek, M. ;

Kneba, M. ;

Ritgen, M. .

LEUKEMIA, 2009, 23 (11) :2007-2017

[3]

Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia:: High response rate and disease eradication [J].

Bosch, Francesc ;

Ferrer, Ana ;

Villamor, Neus ;

Gonzalez, Marcos ;

Briones, Javier ;

Gonzalez-Barca, Eva ;

Abella, Eugenia ;

Gardella, Santiago ;

Escoda, Lourdes ;

Perez-Ceballos, Elena ;

Asensi, Antoni ;

Jose Sayas, Ma ;

Font, Llorenc ;

Altes, Albert ;

Muntanola, Ana ;

Bertazzoni, Paola ;

Rozman, Maria ;

Aymerich, Marta ;

Gine, Eva ;

Montserrat, Ernili .

CLINICAL CANCER RESEARCH, 2008, 14 (01) :155-161

[4]

Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome [J].

Brown, J. R. ;

Kim, H. T. ;

Armand, P. ;

Cutler, C. ;

Fisher, D. C. ;

Ho, V. ;

Koreth, J. ;

Ritz, J. ;

Wu, C. ;

Antin, J. H. ;

Soiffer, R. J. ;

Gribben, J. G. ;

Alyea, E. P. .

LEUKEMIA, 2013, 27 (02) :362-369

[5]

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study [J].

Delgado, J ;

Thomson, K ;

Russell, N ;

Ewing, J ;

Stewart, W ;

Cook, G ;

Devereux, S ;

Lovell, R ;

Chopra, R ;

Marks, DI ;

Mackinnon, S ;

Milligan, DW .

BLOOD, 2006, 107 (04) :1724-1730

[6]

Genomic aberrations and survival in chronic lymphocytic leukemia. [J].

Döhner, H ;

Stilgenbauer, S ;

Benner, A ;

Leupolt, E ;

Kröber, A ;

Bullinger, L ;

Döhner, K ;

Bentz, M ;

Lichter, P .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (26) :1910-1916

[7]

P53 GENE DELETION PREDICTS FOR POOR SURVIVAL AND NONRESPONSE TO THERAPY WITH PURINE ANALOGS IN CHRONIC B-CELL LEUKEMIAS [J].

DOHNER, H ;

FISCHER, K ;

BENTZ, M ;

HANSEN, K ;

BENNER, A ;

CABOT, G ;

DIEHL, D ;

SCHLENK, R ;

COY, J ;

STILGENBAUER, S ;

VOLKMANN, M ;

GALLE, PR ;

POUSTKA, A ;

HUNSTEIN, W ;

LICHTER, P .

BLOOD, 1995, 85 (06) :1580-1589

[8]

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus [J].

Dreger, P. ;

Corradini, P. ;

Kimby, E. ;

Michallet, M. ;

Milligan, D. ;

Schetelig, J. ;

Wiktor-Jedrzejczak, W. ;

Niederwieser, D. ;

Hallek, M. ;

Montserrat, E. .

LEUKEMIA, 2007, 21 (01) :12-17

[9]

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial [J].

Dreger, Peter ;

Doehner, Hartmut ;

Ritgen, Matthias ;

Boettcher, Sebastian ;

Busch, Raymonde ;

Dietrich, Sascha ;

Bunjes, Donald ;

Cohen, Sandra ;

Schubert, Joerg ;

Hegenbart, Ute ;

Beelen, Dietrich ;

Zeis, Matthias ;

Stadler, Michael ;

Hasenkamp, Justin ;

Uharek, Lutz ;

Scheid, Christof ;

Humpe, Andreas ;

Zenz, Thorsten ;

Winkler, Dirk ;

Hallek, Michael ;

Kneba, Michael ;

Schmitz, Norbert ;

Stilgenbauer, Stephan .

BLOOD, 2010, 116 (14) :2438-2447

[10]

Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation [J].

Farina, Lucia ;

Carniti, Cristiana ;

Dodero, Anna ;

Vendramin, Antonio ;

Raganato, Anna ;

Spina, Francesco ;

Patriarca, Francesca ;

Narni, Franco ;

Benedetti, Fabio ;

Olivieri, Attilio ;

Corradini, Paolo .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (05) :654-662

← 1 2 3 →